Skip to main content

Information updates

Novalac Allergy Infant Formula Update

Aspen Pharmacare Australia Pty Ltd took over the distribution of the Novalac infant formula range from Bayer Pharmaceuticals on 1st June 2022. 

As the distributor of Novalac Allergy, Aspen Pharmacare Australia Pty Ltd www.aspenpharma.com.au is working with the global manufacturer to ensure supply, particularly as babies who are fed Novalac Allergy Infant Formula are vulnerable patients with specialised nutrition requirements.

In recent months, global supply chains have come under strain from the impact of COVID-19 and geopolitical events such as the conflict zones in Europe. With the higher-than-average demand, stock levels of Novalac Allergy Infant Formula continue to be depleted at an accelerated pace.  

While limited availability continues, parents and carers should contact their local pharmacy to check stock levels prior to going in-store and, if the product cannot be found in-store, try online options: chemistwarehouse.com.au or priceline.com.au.

Some minor improvements to the Novalac Allergy formulation

Novalac  is constantly looking to improve the formulations to better meet the needs of babies with common feeding problems. Novalac Allergy has made improvements to some of the ingredients. The fish oil has now been replaced with 100% plant source which is rich in DHA and ARA, we have replaced glucose syrup with maltodextrin, as a result the volume per scoop and Nutrition Information Panel (NIP) has been adjusted accordingly. Please be assured that these improvements in Novalac Allergy continue to meet the nutrient requirements according to the FSANZ guidelines 2.9.5.

It is recommended that parents/carers speak to their healthcare professional who can provide medical advice about milk-substuiute products specifically for their baby if they have cow's milk (dairy) allergy, which are listed on the ASCIA website www.allergy.org.au/hp/papers/guide-for-milk-substitutes-cows-milk-allergy

This news item was issued on 24 March 2022 and updated on 10 October 2022 by the Australasian Society of Clinical Immunology and Allergy (ASCIA), the peak professional body for clinical immunology and allergy in Australia and New Zealand.